Filter
47
Featured
Language
Document type
No document type
25
Guidelines
15
Fact sheets
3
Studies & Reports
2
Manuals
1
Resource Platforms
1
Countries / Regions
Western and Central Europe
3
Latin America and the Carribbean
2
South Africa
2
Laos
1
Africa
1
Cambodia
1
Vietnam
1
Authors & Publishers
World Health Organization WHO
14
World Health Organization
11
et al.
5
i-base
4
European AIDS Clinical Society (EACS)
3
M. Vitoria
2
Organización Panamericana de la Salud
2
P. Clayden
2
UNAIDS
2
World Health Organization (WHO)
2
A. Adesina
1
A. Gupta
1
B. Dongmo-Nguimfack
1
Clinical Info HIV
1
D. K. Mubangizi
1
Deparment of Health, South Africa
1
HIV i-Base
1
J Acquir Immune Defic Syndr
1
J. Stover
1
L. Myer
1
M. Auton
1
M. Doherty
1
M. Penazzato
1
M. Smid
1
M. Stahl
1
M. Vitoriaa
1
Médecins Sans Frontières
1
MSF Access Campaign
1
MSF Médecins sans Frontières
1
N. Forda
1
National Department of Health South Africa
1
OPS
1
Organisation Mondiale de la Santé OMS
1
Organización Mundial de la Salud (Americas)
1
PAHO
1
Pan American Health Organisation PAHO
1
PLOS ONE
1
S. Juneja
1
T. K. Phillips
1
Unitaid
1
WHO (World Health Organisation)
1
Wolters Kluwer Health
1
World Health Organization (Africa)
1
Publication Years
Category
HIV & STI
15
Policies & Guidelines HIV & TB
3
Guidelines
2
COVID-19
1
Women & Child Health
1
Capacity Building
1
Pharmacy & Technologies
1
Toolboxes
Men experience increased risk of morbidity and mortality across all ten major contributors to poor health and continue to lag behind women regarding HIV services and other health outcomes. Globally, men now account for the majority of new HIV infections. In 2022, only 72% of men living with HIV (age... more
This technical report summarizes the discussions on the status of programmatic transition to tenofovir, lamivudine and dolutegravir (TLD) in low– and middle- income countries, addressing the best practices and major challenges faced by HIV programmes. The latest data on safety and efficacy of do... more
July 2021. This publication brings together important clinical and programmatic updates produced by WHO since 2016 and provides comprehensive, evidence-informed recommendations and good practice statements within a public health, rights-based and person-centred approach. These guidelines bring in... more
These guidelines provide new and updated recommendations on the use of point-of-care testing in children under 18 months of age and point-of-care tests to monitor treatment in people living with HIV; the treatment monitoring algorithm; and timing of antiretroviral therapy (ART) among people living w... more
These guidelines provide new and updated recommendations on the use of point-of-care testing in children under 18 months of age and point-of-care tests to monitor treatment in people living with HIV; the treatment monitoring algorithm; and timing of antiretroviral therapy (ART) among people living w... more
The federally approved medical practice guidelines for HIV/AIDS are developed by panels of experts in HIV care. More information about the panels can be found in each set of guidelines. The guidelines are available in multiple formats. The brief versions of the guidelines are compilations of the pa... more
This technical note summarizes the consolidated guidelines and adapts them to the context of Latin America and the Caribbean, in order to adequately monitor the number of people on ART. For this purpose, guidance is presented on the indicators and the methodology to know more precisely the number of... more
Version 10.1_5 October 2020 These Guidelines are available in different formats: As a paper booklet, a PDF, a mobile app, and now also as a website. The 2019 version of the Guidelines introduces a new drug-drug interaction panel and now consists of six main sections, including a general overview ... more
15 January 2021
Q&A on COVID-19, HIV and antiretrovirals - Hỏi Đáp về COVID-19, HIV và thuốc antiretrovirals (ARVs)
Médecins sans Frontières access campaign Issue Brief Accessed: 28.11.2019
WHO/HIV/SIP Accessed: 28.11.2019
www.i-Base.info Accessed: 28.11.2019

Annex 3. Dosages of ARV drugs

World Health Organization (2019) C_WHO
Accessed: 19.10.2019